Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly jumped by 14.30 percent on Thursday to end at $839.96 each as investor sentiment was buoyed by announcements that its new GLP-1 weight loss pill, orforglipron, demonstrated positive results ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule ...

Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...